Drug Profile
Arbekacin - Nobelpharma
Alternative Names: Arbekacin sulfate - Nobelpharma; Nonsense readthrough compound; NPC-14Latest Information Update: 25 Aug 2016
Price :
$50
*
At a glance
- Originator Nobelpharma
- Class Aminoglycosides; Antibacterials; Cyclohexanols; Cyclohexylamines; Hexosamines
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Duchenne muscular dystrophy
Most Recent Events
- 25 Aug 2016 Arbekacin is still in phase II trials for Duchenne muscular dystrophy in Japan (IV)
- 02 Sep 2015 Nobelpharma completes enrolment in its phase II trial for Duchenne muscular dystrophy in Japan (NCT01918384)
- 14 Aug 2013 Nobelpharma, Kobe University and Japan Medical Association plan a phase II trial for Duchenne muscular dystrophy in Japan (NCT01918384)